Elsevier

European Urology

Volume 72, Issue 2, August 2017, Pages 171-174
European Urology

Platinum Priority – Brief Correspondence
Editorial by Andrea Minervini , Riccardo Campi, Alberto Lapini and Marco Carini on pp. 175–176 of this issue
Complications After Metastasectomy for Renal Cell Carcinoma—A Population-based Assessment

https://doi.org/10.1016/j.eururo.2017.03.005Get rights and content

Abstract

Metastasectomy has long been considered a valid treatment option for patients with oligometastatic renal cell carcinoma (oligo-mRCC). However, the literature on complications in this setting is scarce. Our objective was to describe in-hospital complications after metastasectomy in a contemporary cohort of patients with mRCC. Using the National Inpatient Sample database (2000–2011), 45 279 mRCC patients were identified. Of those, 1102 underwent metastasectomies. The metastatic sites were the lungs, bone, liver, lymph nodes, adrenal glands, and brain in, respectively, 52%, 29%, 19%, 14%, 11%, and 3.4% of patients. The overall complication rate was 45.7%. Major complications (Clavien III–V) constituted 27.5%. Resections of hepatic lesions were significantly associated with higher odds of overall complications compared with any other site (odds ratio 2.59, 95% confidence interval 1.84–3.62, p < 0.001). While metastasectomy remains a potential treatment option in RCC with oligometastatic disease, the associated complication rates are non-negligible; therefore, careful patient selection is warranted.

Patient summary

We studied outcomes of patients with metastatic kidney cancer treated with metastasectomy. While metastasectomy is a treatment option for metastatic renal cell carcinoma, complications are not insignificant and our results may guide preoperative counseling.

Cited by (45)

  • Role of Surgery in Metastatic Renal Cell Carcinoma

    2023, Hematology/Oncology Clinics of North America
  • Stereotactic Ablative Radiation (SAbR) for Oligometastatic RCC

    2021, Seminars in Radiation Oncology
    Citation Excerpt :

    One population-based assessment of 1102 mRCC patients who underwent metastasectomy reported an overall complication rate of 45.7%, with major complications constituting 27.5% of procedures. Resections of hepatic lesions were significantly associated with higher odds of overall complications compared with any other site.30 Despite high local control after metastasectomy, most surgically treated patients ultimately develop systemic recurrence.

  • A drug delivery perspective on intratumoral-immunotherapy in renal cell carcinoma

    2021, Urologic Oncology: Seminars and Original Investigations
  • The Evolving Role of Metastasectomy for Patients with Metastatic Renal Cell Carcinoma

    2020, Urologic Clinics of North America
    Citation Excerpt :

    Alternatively, higher-volume centers may be more likely to publish data for metastasectomy,16 which may be skewed because of better outcomes demonstrated at centers with higher volume of mRCC patients.71 Age, comorbidities, and hepatic surgery are associated with higher risk of major complications.69 Alternatives to surgical metastasectomy include radiation and thermal ablation.

  • Predictive factors for recurrence after complete metastasectomy in patients with metastatic renal cell carcinoma in the targeted therapy era

    2020, Urologic Oncology: Seminars and Original Investigations
    Citation Excerpt :

    They investigated 45,279 patients with mRCC who underwent metastasectomy and showed that overall and major (Clavien-Dindo 3–4) complications occurred in 45.7% and 25.1% of patients, respectively, and the in-hospital mortality rate was 2.4%. In addition, predictors for major complications were a high comorbidity burden, and resections of hepatic lesions were significantly associated with higher odds of overall complications compared with other sites [11]. Therefore, indication for metastasectomy should be carefully considered.

View all citing articles on Scopus

Please visit www.eu-acme.org/europeanurology to read and answer questions on-line. The EU-ACME credits will then be attributed automatically.

1

These authors contributed equally.

View full text